1[1]Douglas E. The renin-angiotensin system and fibrinolysis [J ].Am J Cardiol, 1997,79(5A): 12 ～ 15.
2[2]Lindoff C, Peterson F, Leesnder I, et al. Tranclermal estrogen replacement therapy: benificial effects on hemostatic risk factors for cardiovascular disease[ J ]. Maturitas, 1996,24: 43 ～ 50.
3[3]Abbasi F, Mclaughlin T, Lamendola C, et al. Comparason of plasminogen activitor inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women [J ]. Arterioscler Thromb Vasc Biol, 1999,19:2818～2821.
4[4]Poli KA, Tofler GH, Larson MG, et al. Association of blood pressure with fibrinolytic potential in the Framingham Offspring Study[J ]. Circulation, 2000,101: 264 ～ 269.
5[5]Bavenbolm P, de Faire U, Landou C, et al. Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function[J ]. Eur Heart J, 1998, 19:402～410.
6[6]Thogersen AM, Jamsson JH, Boman K, et al. High plasminogen activator inhibitor levels in plasma precede a first acute myocardial infarction in both man and woman. Evidence for the fibrinolytic system as an independent prinary risk factor[J ]. Circulation, 1998,88:2030 ～ 2034.
7[7]Etizman DT,Westrick RJ, Xu Z, et al. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery[J]. Blood, 2000,96:4215.
8[8]Nishimura H, Tsuji H, Masuda H, et al. The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells [J ]. Thromb Haemost, 1999,82: 1516～ 1521.
9[9]Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells[J]. J Clin Invest, 1995,95(3):995～1001.
10[10]Sironi L, Calvio AM, Arnaboldi L, et al. Effects of valsartan on amngiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells[ H]. Hypertension,2001,37: 961 ～ 967.
